Gastroesophageal Cancer
Advertisement
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
For postoperative morbidity and mortality, surgery alone had the highest probability rate.
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
Standard treatment for ESCC includes esophagectomy, but the surgery is often linked to complications and reduced QoL.
Researchers noted that CIPN was negatively connected to HRQOL across all therapy groups.
The study compared neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy.
Dr. Joel Rubenstein discusses the recent American Gastroenterological Association guideline on EET for Barrett's esophagus.
The risk of developing esophageal cancer is between 30 and 125 times higher in patients with Barrett's esophagus.
Interleukins can aid in the development of a tumor-directed immune response to improve immunotherapy.
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
qFME with oral administration of bevacizumab-800CW and cetuximab-800CW is feasible, and can shorten procedure time.
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.